Risk factors for lymph node metastasis of soft tissue sarcomas of the head, neck, and extremities, and the clinical significance of negative lymph node dissection

Qi-Kun Liu†, Xiao-Jun Yu†, Ying-Guang Wang, Rui Lu, Shan-Xi Wang, Hao-Ran Xu and Hao Kang*

Abstract
Background: This study sought to define the risk factors for lymph node metastasis (LNM) of soft tissue sarcomas (STS) of the head, neck, and extremities, and the clinical significance of negative lymph node dissection (NLND).

Methods: STS patient data in the Surveillance, Epidemiology, and End Results (SEER) database from 1988 to 2015 were extracted and pooled. Logistics regression analysis was used to identify risk factors for LNM, Cox proportional hazards and Fine–Grey’s models were used for survival analysis, and Propensity score matching analysis (PSM) was used to assess the impact of NLND on patient prognosis.

Results: A total of 3276 patients were enrolled in the study, of whom 283 (8.6%) developed LNM. Rhabdomyosarcoma had the highest rate of LNM (25.3%), followed by clear cell sarcoma (16.8%) and epithelioid sarcoma (12.4%), while leiomyosarcoma had the lowest rate of LNM (1.3%). Sex, tumor size, grade, histology, and site were significantly associated with LNM. For specific histologic subtypes of STS, NLND significantly improves overall survival (HR: 0.718, 95%CI 0.535–0.962; \( P = 0.026 \)) and cancer-specific survival (HR: 0.699, 95%CI 0.506–0.967; \( P = 0.031 \)) and reduces cancer-specific mortality (Gray's test, \( P = 0.017 \)). However, NLND did not improve overall survival (\( P = 0.46 \)) or reduce cancer-specific mortality (Gray's test, \( P = 0.772 \)) of patients with leiomyosarcoma.

Conclusions: Histology is an independent risk factor for LNM in STS of the head, neck, and extremities. Prophylactic NLND treatment was necessary and had a clinical benefit for patients with STS who were at high risk for LNM but had no significant impact on the prognosis of patients with leiomyosarcoma.

Keywords: Soft tissue sarcoma, Lymph node metastasis, Risk factors, Prognosis, Negative lymph node dissection

Introduction
Soft tissue sarcomas (STS) are rare heterogeneous solid tumors of mesenchymal cell origin of which more than 50 different histologic subtypes have been identified to date [1]. Common subtypes of STS include malignant fibrous histiocytoma, liposarcoma, and leiomyosarcoma. The extremities (30.7%), truncal or visceral locations (50.4%), retroperitoneum (11.7%), and head or neck (7.2%) are the most common primary sites [2]. These mesenchymal tumors have a propensity for hematogenous metastasis with distant metastasis rates ranging from 12 to 37.7% [3, 4]. Lung and bone metastasis is common [4, 5], while lymph node metastasis (LNM) is relatively rare in most STS [6], with an incidence of 0.9–6% [3, 7–10]. The rate of LNM varies greatly by sarcoma type. A retrospective
studies by Keung et al. involving 89,870 extremity/trunk STS found that small cell sarcoma (19%), clear cell sarcoma (16%), epithelioid (13%), and angiosarcoma (6%) were the subtypes with the highest incidence of LNM [8]. Sawamura et al. found that the STS with the highest rate of LNM were clear cell sarcoma (38%), rhabdomyosarcoma (37%), epithelioid sarcoma (30%), angiosarcoma (20%), and Ewing's sarcoma of soft tissue (16%) [9]. Some studies have classified clear cell sarcoma, rhabdomyosarcoma, epithelioid sarcoma, and angiosarcoma as subtypes with a high risk of LNM [11]. Based on these findings, six STS subtypes with a high risk of LNM were selected for analysis in this study.

It is generally believed that LNM is associated with a poorer prognosis [3, 10, 11]. Crettenand et al. found that LNM reduces both overall (median survival: 15.1 vs. 73.9 months, respectively; \( p = 0.002 \)) and disease-free survival (median disease-free survival: 8.0 vs. 33.0 months, respectively; \( p = 0.006 \)) [12]. Metastatic disease is also the first sign of many occult malignancies, and metastases can cause complications that impair quality of life [13, 14]. The 8th edition of the American Joint Committee on Cancer (AJCC) staging system defines lymph node involvement as stage IV disease in sarcomas of the trunk and extremities. Thus, identifying patients who are at risk for LNM and defining LNM-specific risk factors is important for clinical decision-making and patient prognosis. However, identifying these patients has always been a challenge. Identifying at-risk patients has been a challenge, however, and the prognostic factors of STS patients without LNM who have undergone surgical treatment are not well-defined. At present, there are no studies on the prognostic impact of NLND treatment on patients with STS of the head, neck, and extremities. Thus, the present study sought to identify the risk factors for LNM in STS patients with six histological subtypes, the prognostic factors of patients without LNM, and the impact of NLND treatment on patient prognosis.

Materials and methods
Data sources and patient selection
Clinical data for this retrospective study was obtained from the Surveillance Epidemiology and End Results (SEER) database. The SEER database is free and publicly accessible, and individual consent for this retrospective analysis was waived because the patient information is anonymous. The study was conducted according to the Declaration of Helsinki (as revised in 2013). Patient data were downloaded using the SEER*Stat software (version 8.3.6). The final study population was selected based on the following inclusion criteria: (1) diagnosis based on positive pathology, (2) tumor sites in the head, neck, and extremities, (3) histological codes: 8890–1, 8893–6, 8900–8902, 8910, 8912, 8920, 9120, 9130, 9133, 9150, 9170, 9260, 9364, 9473, 8804, 8005, 9004, 4) specified tumor was the first primary tumor at the time of diagnosis, and 5) available data on lymph node status and survival month. The detailed inclusion and exclusion process is shown in Fig. 1.

Variables and outcomes
The following information was collected for each patient: (1) demographic variables including age, sex, race, marital status, and year of diagnosis, (2) oncological variables including tumor size, site, laterality, stage, grade, lymph node status, and histology, and (3) therapeutic variables including surgery and lymph node dissection. Prior research has shown that the oncologic features of STS patients differ by age group. For this study, age groups included those < 19 years of age (children and adolescents) and \( \geq 19 \) years of age (adults). Since SEER began including information on lymph node dissection in 1988, data were only collected for cases recorded from 1988 to 2015. The years of diagnosis were divided into two categories: 1988–2005 and 2006–2015. Tumor histological subtypes were determined using the “ICD-O-3 Hist/Behav” field in the SEER database. Six STS types with the following histological codes were included in the study: 8890–1, 8893–6, 8900–8902, 8910, 8912, 8920, 9120, 9130, 9133, 9150, 9170, 9260, 9364, 9473, 8804, 8005, and 9044. Tumor sites were divided into three groups according to the “Primary Site—labeled” field in the SEER database. Staging information was obtained according to the SEER historic stage A (1973–2015) field. Lymph node status information was obtained from the “EOD 10-nodes (1988–2003)” and “CS-lymph nodes (2004–2015)” fields for different periods, and further divided into negative (N0) and positive (N1). Regional lymph node dissection information was obtained from the “Regional nodes examined (1988+)” fields. Lymph node “dissection” was defined as the removal of most or all of the nodes in the lymph node chains that drain the area around the primary tumor, include lymphadenectomy, radical node dissection, and lymph node stripping. Patients with a history of lymph node aspiration or core biopsy, sentinel node procedures, or an uncertain number of removed lymph nodes were excluded. The patients were divided into non-NLND and NLND groups based on examined lymph node (ELN) data. Optimal tumor size cutoff values were defined using X-tile software (version 3.6.1) and divided into the following groups: < 4, 4–10, and \( \geq 10 \) cm (Fig. 2). The primary outcomes were overall survival, defined as the time from diagnosis to death of any cause, and cancer-specific survival, defined as the time from diagnosis to death resulting from the primary STS.
**Statistical analysis**

Categorical variates are presented as frequencies and percentages, and continuous variates are presented as the median and interquartile range (IQR). For categorical variables, the Chi-square test was used to analyze between-group differences and for continuous variables, the Wilcoxon rank-sum tests was used. For baseline variables, univariate analysis using the Kaplan–Meier curve and the log-rank test was performed. When the $P$ value was <0.1, variables were included in multivariate Cox regression analysis to identify independent prognostic factors and estimate the hazard ratio (HR) and 95% confidence interval (CI) of each covariate. Risk factors for LNM in STS of the head, neck, and extremities were identified using univariate and multivariate logistic regression analyses. Then, we further analyzed the effect of NLND on the prognosis of patients with STS. Taking non-cancer-specific death as a competing risk to cancer-specific death, cumulative incidence function curves for patients with NLND were plotted, and Gray’s test was performed to compare fatality rates. Multivariate analysis was performed on the cohort data to identify independent prognostic factors by using the Cox proportional hazards regression model and the Fine and Gray’s regression model. In the Cox analysis, patients who were alive at the last follow-up were considered as censored cases, while in the Fine and Gray’s regression model, non-cancer-specific death was considered a competing risk, and we used the sub-distribution hazards ratio (SHR) was used to represent the contribution of each variable to cancer-specific death. The effect of NLND on patient prognosis was also investigated. To eliminate the impact of other factors and minimize the selection bias between the NLND and non-NLND groups, patients from each group were matched 1:1 using propensity score matching (PSM). Chi-square was used to compare the clinicopathological features of the NLND and non-NLND groups. Variables that differed between the two groups as well as those thought to influence treatment for negative lymph nodes were included in the matching analysis. After PSM, Kaplan–Meier and cumulative incidence function curves were created. All statistical analyses were performed using R software (version 3.6.2). The R “survival” package was used for the Kaplan–Meier curve and the Cox regression analysis, the “Matchit” package was used for the PSM analysis, and the “timereg” and “cmprsk” packages were used for the competing risk analysis. A two-sided $P$ value of <0.05 was considered statistically significant.
Results

Demographics and clinical characteristics of patients with STS of the head, neck, and extremities

A total of 3276 eligible cases were included in this study. The median age (IQR range) of the entire cohort population was 53 years (31–69 years). The lymph node positivity rate for the entire cohort was 8.6% and varied significantly between tumor types (Fig. 3A, \(P < 0.001\)). Lymph node positivity was the highest for rhabdomyosarcoma (25.3%), followed by clear cell sarcoma (16.8%) and epithelioid sarcoma (12.4%), and was the lowest for leiomyosarcoma (1.3%). The cohort was divided into a negative lymph node group (NLN) and a positive lymph node group (PLN). Patients in the PLN group were significantly younger than those in the NLN group [median (IQR), 24 years (10–51 years) vs. 54 years (35–70 years), respectively; \(P < 0.001\)] (Table 1). In the PLN group, tumors were mostly located in the

**Fig. 2** Optimal tumor size cut-off values according to cancer-specific survival by X-tile analysis. X-tile software was used to calculate the cut-off value of tumor size (A and B). The cohort was divided into low (purple), medium (gray), and high (blue) survival groups according to the cut-off value for tumor size (C). The cut-off value for tumor size was validated by Kaplan–Meier curve (D).
head, neck, and lower extremities, while in the NLN
group, they were primarily found in the lower extremi-
ties (73.1% vs. 55.7%, respectively; \( P < 0.001 \)). Rhab-
domyosarcoma was predominant in the PLN group
(51.9%), while leiomyosarcoma was predominant in the
NLN group (52.7%). The rate of NLND was higher in
the PLN group than in the NLN group (56.5% vs. 12.6%,
respectively; \( P < 0.001 \)). There were also significant dif-
fferences in race, marital status and tumor grade, stage,
size, laterality, and surgery between the two groups
(\( P < 0.05 \)). The median survival time was significantly
shorter in the PLN than NLN groups [median (IQR),
23 months (11.5–74.5 months) vs. 55 months (22–
112 months), respectively; \( P < 0.001 \)].
Table 1  Characteristics of enrolled patients divided into lymph node-negative and node-positive groups

| Characteristics                  | Total  | Negative | Positive | p value<sup>a</sup> |
|----------------------------------|--------|----------|----------|---------------------|
| N (%)                            | 3276   | 2993 (91.4%) | 283 (8.64%) | <0.001               |
| Age, median (IQR<sup>b</sup>)    | 53.0 [31.0;69.0] | 54.0 [50.0;70.0] | 24.0 [10.0;51.0] | <0.001               |
| Age, years (%)                   |        |          |          |                     |
| < 19                             | 537 (16.4%) | 411 (13.7%) | 126 (44.5%) | <0.001               |
| ≥ 19                             | 2739 (83.6%) | 2582 (86.3%) | 157 (55.5%) |                     |
| Race (%)                         |        |          |          | 0.002                |
| White                            | 2700 (82.4%) | 2487 (83.1%) | 213 (75.3%) |                     |
| Black                            | 338 (10.3%) | 293 (9.79%) | 45 (15.9%) |                     |
| Other<sup>c</sup>                | 238 (7.26%) | 213 (7.12%) | 25 (8.83%) |                     |
| Sex (%)                          |        |          |          | 0.055                |
| Female                           | 1398 (42.7%) | 1293 (43.2%) | 105 (37.1%) |                     |
| Male                             | 1878 (57.3%) | 1700 (56.8%) | 178 (62.9%) |                     |
| Year of diagnosis (%)            |        |          |          | 0.664                |
| 1988–2005                        | 1286 (39.3%) | 1171 (39.1%) | 115 (40.6%) |                     |
| 2006–2015                        | 1990 (60.7%) | 1822 (60.9%) | 168 (59.4%) |                     |
| Site (%)                         |        |          |          | <0.001               |
| Head, Face, Neck                 | 676 (20.6%) | 581 (19.4%) | 95 (33.6%) |                     |
| Upper limb, shoulder             | 820 (25.0%) | 744 (24.9%) | 76 (26.9%) |                     |
| Lower limb, hip                  | 1780 (54.3%) | 1668 (55.7%) | 112 (39.6%) |                     |
| Grade (%)                        |        |          |          | <0.001               |
| I + II                           | 687 (21.0%) | 680 (22.7%) | 7 (2.47%) |                     |
| III + IV                         | 1325 (40.4%) | 1216 (40.6%) | 109 (38.5%) |                     |
| Unknown                          | 1264 (38.6%) | 1097 (36.7%) | 167 (59.0%) |                     |
| Laterality (%)                   |        |          |          | <0.001               |
| Left                             | 1382 (42.2%) | 1285 (42.9%) | 97 (34.3%) |                     |
| Right                            | 1372 (41.9%) | 1255 (41.9%) | 117 (41.3%) |                     |
| Unknown                          | 522 (15.9%) | 453 (15.1%) | 69 (24.4%) |                     |
| Histology (%)                    |        |          |          | <0.001               |
| Leiomyosarcoma                   | 1598 (48.8%) | 1577 (52.7%) | 21 (7.42%) |                     |
| Rhabdomyosarcoma                 | 581 (17.7%) | 434 (14.5%) | 147 (51.9%) |                     |
| Angiosarcoma                     | 469 (14.3%) | 431 (14.4%) | 38 (13.4%) |                     |
| Ewing sarcoma                    | 262 (8.00%) | 237 (7.92%) | 25 (8.83%) |                     |
| Epithelioid sarcoma              | 217 (6.62%) | 190 (6.35%) | 27 (9.54%) |                     |
| Clear cell sarcoma               | 149 (4.55%) | 124 (4.14%) | 25 (8.83%) |                     |
| Stage (%)                        |        |          |          | <0.001               |
| Localized                        | 2177 (66.5%) | 2177 (72.7%) | 0 (0.000%) |                     |
| Regional                         | 820 (25.0%) | 636 (21.2%) | 184 (65.0%) |                     |
| Distant                          | 279 (8.52%) | 180 (6.01%) | 99 (35.0%) |                     |
| Surgery (%)                      |        |          |          | <0.001               |
| No                               | 331 (10.1%) | 237 (7.92%) | 94 (33.2%) |                     |
| Yes                              | 2945 (89.9%) | 2756 (92.1%) | 189 (66.8%) |                     |
| Lymph nodes dissection (%)       |        |          |          | <0.001               |
| No                               | 2738 (83.6%) | 2615 (87.4%) | 123 (43.5%) |                     |
| Yes                              | 538 (16.4%) | 378 (12.6%) | 160 (56.5%) |                     |
| Size, cm (%)                     |        |          |          | <0.001               |
| < 4                              | 1362 (41.6%) | 1297 (43.3%) | 65 (23.0%) |                     |
| 4–10                             | 1300 (39.7%) | 1163 (38.9%) | 137 (48.4%) |                     |
| ≥ 10                             | 614 (18.7%) | 533 (17.8%) | 81 (28.6%) |                     |
| Marital status (%)               |        |          |          | <0.001               |
Table 1 (continued)

| Characteristics | Total       | Negative | Positive | p valuea |
|-----------------|-------------|----------|----------|----------|
| Married         | 1531 (46.7%)| 1455 (48.6%) | 76 (26.9%) |           |
| Never married   | 1123 (34.3%)| 939 (31.4%)  | 184 (65.0%)|           |
| Divorced/Widowed/Separated | 503 (15.4%) | 484 (16.2%)  | 19 (6.71%) |           |
| Unknown         | 119 (3.63%) | 115 (3.84%)  | 4 (1.41%) |           |
| Survival months, median (IQR) | 52.0 [21.0;110] | 55.0 [22.0;112] | 23.0 [11.5;74.5] | < 0.001 |

a Chi-square test, bold values mean p < 0.05, which represent statistically significant
b Interquartile range
c American Indian/Alaska Native, Asian/Pacific Islander

Risk factors for LNM of STS in head and neck and extremities

Our results suggested that patients with LNM have a poorer prognosis (Fig. 3B), reinforcing the need to identify risk factors. Univariate logistics and multivariate cox regression analyses were used on the target cohort to identify risk factors for LNM. Variables with P values < 0.1 in the univariate analysis were included in the multivariate analysis to adjust for potential confounding (Table 2). The results indicated that patients who were male [odds ratio (OR): 1.291, 95% CI 1.012–1.646; P = 0.040], had grade III + IV (OR: 3.930, 95% CI 1.805–8.554; P = 0.001) had grade unknown (OR: 5.033, 95% CI 2.325–10.895; P < 0.001) tumors, a diagnosis of rhabdomyosarcoma (OR: 9.598, 95% CI 5.719–16.110; P < 0.001), angiosarcoma (OR: 5.459, 95% CI 3.163–9.419; P < 0.001), Ewing sarcoma (OR: 4.026, 95% CI 2.205–7.351; P < 0.001), epithelioid sarcoma (OR: 7.965, 95% CI 4.435–14.307; P < 0.001), or clear cell sarcoma (OR: 11.587, 95% CI 6.39–20.989; P < 0.001), or tumors that were 4–10 cm (OR: 2.080, 95% CI 1.521–2.845; P < 0.001) or ≥10 cm (OR: 4.676, 95% CI 3.250–6.728; P < 0.001) in size had a higher risk of LNM. Patients with tumors on the upper (OR: 0.549, 95% CI 0.345–0.876; P = 0.012) or lower limbs (OR: 0.394, 95% CI 0.249–0.626; P < 0.001) had a lower risk of LNM than those with tumors on the head, face, and neck.

Prognostic factors for patients with STS without LNM in the head, neck, and extremities

The 2756 patients without LNM were included in the survival analysis. To adjust for potential confounding, multivariate Cox regression for cancer-specific survival was conducted by including all possible prognostic factors. Age, marital status and tumor grade, histology, stage, and size were independent prognostic factors for cancer-specific survival (Additional file 1: Table S1). In the Cox proportional hazards regression analysis for cancer-specific survival, patients dying for other reasons are usually censured because death from other causes can prevent the occurrence of target events. Considering death from other causes as competing risk, Fine and Gray’s regression analysis was also conducted. Factors associated with cancer-specific survival after controlling for competing risks included age, marital status and tumor histology, size, grade, and stage. Patients ≥19 years of age (sHR, 1.876, 95% CI 1.341–2.625; P < 0.001), with tumor grade III + IV (sHR: 1.771, 95% CI 1.422–2.206; P < 0.001), other sarcomas, and clear cell sarcomas. In all cases, the NLND was an independent risk factor for the prognosis of five subtypes of STS at high risk for LNM: rhabdomyosarcomas, angiosarcomas, Ewing sarcomas, epithelioid sarcomas, and clear cell sarcomas. In all cases, the NLND group had significantly higher overall and cancer-specific survival rates (Fig. 4A, B). Cumulative incidence function curves were also plotted to compare the differences in cancer-specific mortality between the two groups. As shown in Fig. 6A, the cumulative incidence of cancer-specific death was lower in the NLND group than in the non-NLND group (Gray’s test, P = 0.001).

The effect of NLND on the prognosis of patients with different soft tissue sarcomas

The effect of NLND on the prognosis of patients with different histological STS subtypes was assessed. NLND was an independent risk factor for the prognosis of five subtypes of STS at high risk for LNM: rhabdomyosarcomas, angiosarcomas, Ewing sarcomas, epithelioid sarcomas, and clear cell sarcomas. In all cases, the NLND group had significantly higher overall and cancer-specific survival rates (Fig. 4A, B). Cumulative incidence function curves were also plotted to compare the differences in cancer-specific mortality between the two groups. As shown in Fig. 6A, the cumulative incidence of cancer-specific death was lower in the NLND group than in the non-NLND group (Gray’s test, P = 0.001).
However, NLND did not improve cancer-specific survival in patients with leiomyosarcoma (Fig. 5B). To further clarify the impact of NLND on patient prognosis, PSM analysis was performed. First, Chi-square was used to compare the baseline characteristics of patients in the NLND and non-NLND groups. Results showed significant differences in age, marital status and tumor site, laterality, histology, stage, and size, between the two groups ($p < 0.05$, Table 4). The covariates were then matched to create a new cohort. After PSM, the covariates were balanced between the two groups, and the results further confirmed that NLND significantly improved both overall (HR: 0.718, 95%CI 0.535–0.962; $P = 0.026$) and cancer-specific survival (HR: 0.699, 95%CI 0.506–0.967; $P = 0.031$) (Table 5 and Fig. 4C, D). Patients in the NLND group had significantly lower cancer-specific mortality (Gray’s test, $P = 0.017$) (Fig. 6B), and significantly longer median survival time than patients in the non-NLND group, both before (median: 69 vs. 47 months, respectively; $p < 0.001$) and after PSM (median: 69.5 vs. 57.5 months, respectively; $p = 0.080$). However, NLND did not improve overall survival ($P = 0.46$) or reduce

Table 2: Univariate logistics and multivariate Cox regression analysis for risk factors of lymph node metastasis

| Variables          | Univariate analysis | Multivariate analysis |
|--------------------|----------------------|-----------------------|
|                    | OR (95% CI)          | $p$ value             | OR (95% CI)          | $p$ value             |
| Age, years         |                      |                       |                      |                       |
| < 19               | Reference            |                       | Reference            |                       |
| ≥ 19               | 0.198 (0.153–0.256)  | $< 0.001$             | 0.927 (0.681–1.263)  | 0.633                 |
| Race               |                      |                       |                      |                       |
| White              | Reference            |                       | Reference            |                       |
| Black              | 1.793 (1.272–2.529)  | $0.001$               | 1.293 (0.933–1.791)  | 0.123                 |
| Other              | 1.37 (0.885–2.122)   | 0.158                 | 1.044 (0.687–1.585)  | 0.841                 |
| Sex                |                      |                       |                      |                       |
| Female             | Reference            |                       | Reference            |                       |
| Male               | 1.289 (1.002–1.659)  | $0.048$               | 1.291 (1.012–1.646)  | $0.040$               |
| Site               |                      |                       |                      |                       |
| Head, Face, Neck   | Reference            |                       | Reference            |                       |
| Upper limb, shoulder | 0.625 (0.453–0.861) | $0.004$               | 0.549 (0.345–0.876)  | $0.012$               |
| Lower limb, hip    | 0.411 (0.308–0.548)  | $< 0.001$             | 0.394 (0.249–0.626)  | $< 0.001$             |
| Grade              |                      |                       |                      |                       |
| I + II             | Reference            |                       | Reference            |                       |
| III+IV             | 8.708 (4.032–18.806) | $< 0.001$             | 3.93 (1.805–8.554)   | $0.001$               |
| Unknown            | 14.788 (6.901–31.691)| $< 0.001$             | 5.033 (2.325–10.895) | $< 0.001$             |
| Laterality         |                      |                       |                      |                       |
| Left               | Reference            |                       | Reference            |                       |
| Right              | 1.235 (0.933–1.634)  | 0.14                  | 1.196 (0.912–1.57)   | 0.196                 |
| Unknown            | 2.018 (1.455–2.798)  | $< 0.001$             | 0.792 (0.494–1.27)   | 0.334                 |
| Histology          |                      |                       |                      |                       |
| Leiomyosarcoma     | Reference            |                       | Reference            |                       |
| Rhabdomyosarcoma   | 25.435 (15.906–40.673)| $< 0.001$             | 9.598 (5.719–16.11)  | $< 0.001$             |
| Angiosarcoma       | 6.621 (3.845–11.401) | $< 0.001$             | 5.459 (3.163–9.419)  | $< 0.001$             |
| Ewing sarcoma      | 7.921 (4.365–14.377) | $< 0.001$             | 4.026 (2.205–7.351)  | $< 0.001$             |
| Epithelioid sarcoma| 10.671 (5.917–19.247)| $< 0.001$             | 7.965 (4.435–14.307) | $< 0.001$             |
| Clear cell sarcoma | 15.14 (8.241–27.817) | $< 0.001$             | 11.587 (6.397–20.989)| $< 0.001$             |
| Size, cm           |                      |                       |                      |                       |
| < 4                | Reference            |                       | Reference            |                       |
| 4–10               | 2.351 (1.732–3.191)  | $< 0.001$             | 2.08 (1.521–2.845)   | $< 0.001$             |
| ≥ 10               | 3.032 (2.155–4.267)  | $< 0.001$             | 4.676 (3.25–6.728)   | $< 0.001$             |

OR, odds ratio; CI, confidence interval

Bold values mean $p$ value < 0.05, which represent statistically significant.
cancer-specific mortality (Gray’s test, $P=0.772$) of patients with leiomyosarcoma (Figs. 5C, D, 6D).

**Discussion**

The prognosis for STS patients with metastasis is poor. The primary STS metastasis sites include the lung and bone, with LNM being relatively rare. However, according to the latest AJCC staging guidelines, sarcomas of the trunk and extremities that involve the lymph nodes are defined as stage IV disease [1]. Thus, it is critical to understand the risk factors and prognosis of STS patients with LNM. To date, most studies have assessed all STS together or site- and patient-specific STS. For example, Gusco et al. studied the LNM rate and prognosis of all STS of the extremities [11]. Sherman et al. studied the LNM rate and predictors of adult STS of extremities [15]. The current study included six types of STS of the head, neck, and extremities that are associated with the highest risk of LNM. The prognosis of 2756 STS patients without LNM who received surgical treatment was quantified. This study also clarified the impact of NLND on STS patient prognosis.

In our cohort, rhabdomyosarcoma (25.3%), clear cell sarcoma (16.8%), and epithelioid sarcoma (12.4%) patients had the highest rates of LNM, while leiomyosarcoma patients had the lowest rate of LNM (1.3%). This is consistent with previously reported rates of lymph node-positivity in different STS types (26.7% for rhabdomyosarcoma, 16–18.8% for clear cell sarcoma, and 13–14.5% for epithelioid sarcoma) from several large cohort studies [8, 11, 16]. In children and adolescents (< 19 years of age), rhabdomyosarcoma had the highest lymph node-positivity rate, while in adults (≥ 19 years), clear cell sarcoma had the highest positivity rate. These results are similar to those found in previous studies [8, 15]. This may be the result of differences in the histological subtypes of STS by age. Indeed, rhabdomyosarcoma was the most common STS in children and adolescents and accounts for one-half of pediatric STS [17]. Independent risk factors for LNM were identified using the multivariate Cox proportional risk model. Patients who were male or had STS in the head and neck, high-grade (III+IV), tumors > 4 cm in size, or non-leiomyosarcomas were more likely to have LNM. Several studies have reported similar results. Miccian et al. found that patients with high-grade STS and histology including clear cell, angiosarcoma, rhabdomyosarcoma, and epithelioid (CARE) sarcomas were associated with LNM [7]. Behranwala et al. examined

| Table 3 | Multiple competing risk regression analysis of soft tissue sarcoma of the head, neck, and extremities without lymph node metastasis |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| Variables | sHR (95% CI) | p value |
| Age, years | < 19 Reference | 1.876 (1.341–2.625) | < 0.001 |
| | ≥ 19 | | |
| Sex | Female Reference | 0.96 (0.822–1.120) | 0.60 |
| | Male | | |
| Race | White Reference | 1.098 (0.865–1.393) | 0.44 |
| | Black | 1.031 (0.759–1.400) | 0.84 |
| | Other | | |
| Year of diagnosis | 1988–2005 Reference | 0.917 (0.788–1.066) | 0.26 |
| | 2006–2015 | | |
| Site | Head, Face, Neck Reference | 0.817 (0.475–1.406) | 0.47 |
| | Upper limb, shoulder | 0.926 (0.547–1.568) | 0.77 |
| | Lower limb, hip | | |
| Grade | I+II Reference | 1.771 (1.422–2.206) | < 0.001 |
| | III+IV | | |
| | Other | 1.400 (1.100–1.783) | 0.01 |
| Laterality | Left Reference | 1.100 (0.932–1.300) | 0.26 |
| | Right | 1.581 (0.916–2.729) | 0.10 |
| Histology | Leiomysarcoma Reference | | |
| | Rhabdomyosarcoma | 1.387 (1.080–1.779) | 0.01 |
| | Angiosarcoma | 1.817 (1.477–2.237) | < 0.001 |
| | Ewing sarcoma | 0.807 (0.553–1.178) | 0.27 |
| | Epithelioid sarcoma | 1.463 (1.029–1.980) | 0.03 |
| | Clear cell sarcoma | 2.321 (1.616–3.333) | | |< 0.001 |
| Stage | Localized Reference | 4.428 (3.356–5.843) | | |< 0.001 |
| | Regional | 1.452 (1.220–1.728) | | |< 0.001 |
| Negative lymph nodes dissection | No Reference | 0.838 (0.662–1.061) | 0.14 |
| | Yes | | |
| Size, cm | < 4 Reference | 2.655 (2.174–3.243) | | |< 0.001 |
| | 4–10 | 4.666 (3.699–5.861) | | |< 0.001 |
| | ≥ 10 | | |
| Marital status | Married Reference | 1.116 (0.912–1.366) | 0.29 |
| | Never married | 1.554 (1.272–1.897) | | |< 0.001 |
| | Divorced/widowed/separated | 1.170 (0.746–1.837) | 0.49 |

Table 3 (continued)

| sHR sub-distribution hazard ratio |
|----------------------------------|
| The values in bold indicate that the p value < 0.05, and the results are statistically significant |
2127 STS patients and found a 70% association between high-grade tumors and lymph nodes spread, with LNM more likely appearing in the proximal location of the sarcoma [6]. Sherman et al. analyzed 27,536 extremity soft tissue sarcoma (ESTS) patients from the National Cancer Data Base (2000–2009) and found that histologic subtype, tumor size, and tumor grade were risk factors for LNM [15]. Other studies have shown that LNM also correlates with age and primary site [10, 18], but none have reported an association between gender and LNM. Our results suggest that males are at higher risk of LNM than females (OR: 1.291, 95% CI 1.012–1.646; \(P = 0.040\)).
Studies show that males have a higher predisposition for STS than females, but the extent to which gender affects LNM has not been established [19].

This study also performed a prognostic analysis of 2756 patients without LNM who had undergone surgery. Age, grade, stage, size, histology and marital status were found to be independent prognostic factors for cancer-specific survival. This result is similar to previous studies. A study with patient data also from the SEER database showed that for the historically high-risk extremity, STS, age,
### Table 4 Clinical characteristics of five types of soft tissue sarcomas with a high risk of lymph node metastasis, before and after propensity score matching (PSM)

| Variables                          | Lymph node treatment group in raw data | Lymph node treatment group after PSM |
|------------------------------------|---------------------------------------|--------------------------------------|
|                                    | Non-NLND (n = 968)                   | NLND (n = 260)                       | Non-NLND (n = 244) | NLND (n = 244) | P value |
| Age, median (IQR)                  | 46.0 [22.0;68.0]                     | 26.0 [12.0;47.2]                    | <0.001              | 34.5 [13.0;57.2] | 29.0 [12.0;48.2] | 0.017 |
| Age, years                         |                                       |                                      | <0.001              | 0.703 |
| < 19                               | 196 (20.2%)                         | 97 (37.3%)                         | 81 (33.2%)          | 86 (35.2%)     |
| ≥ 19                               | 772 (79.8%)                         | 163 (62.7%)                        | 163 (66.8%)         | 158 (64.8%)    |
| Race                               |                                       |                                      | 0.468               | 0.039 |
| White                              | 772 (79.8%)                         | 215 (82.7%)                        | 180 (73.8%)         | 203 (83.2%)    |
| Black                              | 107 (11.1%)                         | 27 (10.4%)                         | 36 (14.8%)          | 24 (9.84%)     |
| Other                              | 89 (9.19%)                          | 18 (6.92%)                         | 28 (11.5%)          | 17 (6.97%)     |
| Sex                                |                                       |                                      | 0.173               | 0.069 |
| Female                             | 421 (43.5%)                         | 126 (48.5%)                        | 99 (40.6%)          | 120 (49.2%)    |
| Male                               | 547 (56.5%)                         | 134 (51.5%)                        | 145 (59.4%)         | 124 (50.8%)    |
| Year of diagnosis                  |                                       |                                      | 0.231               | 1 |
| 1988–2005                          | 364 (37.6%)                         | 109 (41.9%)                        | 105 (43.0%)         | 105 (43.0%)    |
| 2006–2015                          | 604 (62.4%)                         | 151 (58.1%)                        | 139 (57.0%)         | 139 (57.0%)    |
| Site                               |                                       |                                      | <0.001              | 0.711 |
| Head, Face, Neck                   | 260 (26.9%)                         | 52 (20.0%)                         | 59 (24.2%)          | 52 (21.3%)     |
| Upper limb, shoulder               | 200 (20.7%)                         | 97 (37.3%)                         | 87 (35.7%)          | 87 (35.7%)     |
| Lower limb, hip                    | 508 (52.5%)                         | 111 (42.7%)                        | 98 (40.2%)          | 105 (43.0%)    |
| Grade                              |                                       |                                      | 0.127               | 0.899 |
| I+II                               | 114 (11.8%)                         | 25 (9.62%)                         | 22 (9.02%)          | 25 (10.2%)     |
| III+IV                             | 408 (42.1%)                         | 97 (37.3%)                         | 94 (38.5%)          | 93 (38.1%)     |
| Unknown                            | 446 (46.1%)                         | 138 (53.1%)                        | 128 (52.5%)         | 126 (51.6%)    |
| Laterality                         |                                       |                                      | 0.022               | 0.9 |
| Left                               | 364 (37.6%)                         | 119 (45.8%)                        | 111 (45.5%)         | 106 (43.4%)    |
| Right                              | 399 (41.2%)                         | 102 (39.2%)                        | 95 (38.9%)          | 99 (40.6%)     |
| Unknown                            | 205 (21.2%)                         | 39 (15.0%)                         | 38 (15.6%)          | 39 (16.0%)     |
| Histology                          |                                       |                                      | <0.001              | 0.949 |
| Rhabdomyosarcoma                   | 255 (26.3%)                         | 78 (30.0%)                         | 73 (29.9%)          | 78 (32.0%)     |
| Angiosarcoma                       | 344 (35.5%)                         | 42 (16.2%)                         | 44 (18.0%)          | 42 (17.2%)     |
| Ewing sarcoma                      | 184 (19.0%)                         | 19 (7.31%)                         | 18 (7.38%)          | 19 (7.97%)     |
| Epithelioid sarcoma                | 109 (11.3%)                         | 75 (28.8%)                         | 69 (28.3%)          | 62 (25.4%)     |
| Clear cell sarcoma                 | 76 (7.85%)                          | 46 (17.7%)                         | 40 (16.4%)          | 43 (17.6%)     |
| Stage                              |                                       |                                      | 0.05                | 0.661 |
| Localized                          | 663 (68.5%)                         | 171 (65.8%)                        | 169 (69.3%)         | 160 (65.6%)    |
| Regional                           | 238 (24.6%)                         | 79 (30.4%)                         | 65 (26.6%)          | 74 (30.3%)     |
| Distant                            | 67 (6.92%)                          | 10 (3.85%)                         | 10 (4.10%)          | 10 (4.10%)     |
| Size, cm                           |                                       |                                      | <0.006              | 0.597 |
| < 4                                | 368 (38.0%)                         | 121 (46.5%)                        | 109 (44.7%)         | 114 (46.7%)    |
| 4–10                               | 407 (42.0%)                         | 107 (41.2%)                        | 109 (44.7%)         | 99 (40.6%)     |
| ≥ 10                               | 193 (19.9%)                         | 32 (12.3%)                         | 26 (10.7%)          | 31 (12.7%)     |
| Marital status                     |                                       |                                      | <0.001              | 0.858 |
| Married                            | 407 (42.0%)                         | 70 (26.9%)                         | 76 (31.1%)          | 69 (28.3%)     |
| Never married                      | 404 (41.7%)                         | 152 (58.5%)                        | 134 (54.9%)         | 139 (57.0%)    |
| Divorced/Widowed/Separated         | 138 (14.3%)                         | 29 (11.2%)                         | 29 (11.9%)          | 29 (11.9%)     |
| Unknown                            | 19 (1.96%)                          | 9 (3.46%)                          | 5 (2.05%)           | 7 (2.87%)      |
| Survival months (median, IQR)      | 47.0 [17.0;108]                     | 69.0 [268,136]                     | <0.001              | 0.08 |

NLND negative lymph node dissection

The values in bold indicate that the p value < 0.05, and the results are statistically significant
grade, size, surgery, and regional lymph node status were independent disease-specific prognostic factors [11]. Another study found that for epithelial sarcoma, tumor site was a prognostic factor for event-free survival and overall survival, and extremities site had a better prognosis than proximal-type variant [20]. Understanding these

| Variables               | Overall survival HR(95%CI) | Cancer-specific survival HR(95%CI) |
|-------------------------|-----------------------------|-----------------------------------|
| Age, years              |                             |                                   |
| < 19                    | Reference                   | Reference                         |
| ≥ 19                    | 3.218 (1.868–5.543)         | 2.702 (1.49–4.901)                |
| Year of diagnosis       |                             |                                   |
| 1988–2005               | Reference                   | Reference                         |
| 2006–2015               | 1.089 (0.805–1.472)         | 0.581                             |
| Site                    |                             |                                   |
| Head, Face, Neck        | Reference                   | Reference                         |
| Upper limb, shoulder    | 0.577 (0.3–1.108)           | 0.695 (0.324–1.49)                |
| Lower limb, hip         | 0.691 (0.367–1.299)         | 0.789 (0.378–1.649)               |
| Grade                   |                             |                                   |
| I + II                  | Reference                   | Reference                         |
| III 4-IV                | 1.052 (0.613–1.805)         | 1.598 (0.825–3.096)               |
| Unknown                 | 1.19 (0.695–2.037)          | 1.704 (0.872–3.328)               |
| Laterality              |                             |                                   |
| Left                    |                             |                                   |
| Right                   | 1.047 (0.752–1.457)         | 1.024 (0.712–1.474)               |
| Unknown                 | 0.944 (0.481–1.854)         | 1.005 (0.457–2.212)               |
| Histology               |                             |                                   |
| Rhabdomyosarcoma        | Reference                   | Reference                         |
| Angiosarcoma            | 0.942 (0.574–1.545)         | 1.258 (0.724–2.187)               |
| Ewing sarcoma           | 0.397 (0.187–0.845)         | 0.53 (0.236–1.187)                |
| Epithelioid sarcoma     | 0.692 (0.415–1.154)         | 0.825 (0.464–1.466)               |
| Clear cell sarcoma      | 0.785 (0.455–1.355)         | 1.08 (0.593–1.969)                |
| Stage                   |                             |                                   |
| Localized               | Reference                   | Reference                         |
| Regional                | 1.501 (1.078–2.09)          | 1.689 (1.181–2.415)               |
| Distant                 | 3.336 (1.776–6.266)         | 4.308 (2.259–8.217)               |
| NLND                    |                             |                                   |
| No                      | Reference                   | Reference                         |
| Yes                     | 0.718 (0.535–0.962)         | 0.699 (0.506–0.967)               |
| Size, cm                |                             |                                   |
| < 4                     | Reference                   | Reference                         |
| 4–10                    | 1.816 (1.26–2.616)          | 2.3 (1.513–3.496)                 |
| ≥ 10                    | 2.708 (1.636–4.482)         | 3.266 (1.857–5.745)               |
| Marital status          |                             |                                   |
| Married                 | Reference                   | Reference                         |
| Never married           | 0.949 (0.633–1.422)         | 0.976 (0.627–1.52)                |
| Divorced/widowed/separated | 1.971 (1.279–3.037)       | 1.832 (1.13–2.972)                |
| Unknown                 | 1.077 (0.465–2.491)         | 1.046 (0.39–2.804)                |

The values in bold indicate that the p value < 0.05, and the results are statistically significant.
STS characteristics can inform clinical counseling and personalized treatment for patients.

The current study further investigated the association between NLND and disease prognosis. After PSM, we found that NLND was an independent prognosis factor for patients with a high risk of LNM such as rhabdomyosarcomas, angiosarcomas, Ewing sarcomas, epithelioid sarcomas, and clear cell sarcomas. Surprisingly, NLND did not improve the prognosis of leiomyosarcoma before and after PSM. Further analysis showed that patients with leiomyosarcoma were older than the rest five types of sarcomas (median age: 61 vs. 41 years, respectively; \( P < 0.001 \)), and only a small proportion of leiomyosarcoma patients (6.81%) received NLND than those with other tumors (21.2%). Unfortunately, no information about why these patients did not receive a lymph node dissection is available in the SEER database. This may be because these patients are older or have comorbidities or treatment contraindications. In addition, the SEER database does not record information about adjuvant treatments such as radiotherapy and chemotherapy. The absence of these data may affect the accuracy of the results and cause confounding bias so further clinical validation is needed.

Currently, there is no consensus guidelines on how to assess lymph node status in high-risk STS patients. Common strategies for lymph node status assessment include physical examination, ultrasound, CT, MRI, and sentinel lymph node biopsy (SLNB). Radical lymphadenectomy or systemic chemotherapy are often recommended for the treatment of regional lymph node metastases, but treatment modalities are mostly clinician- and center-dependent [19]. Some studies have reported the prognosis of lymph node examination/dissection for STS with LNM, but the result remains controversial. Al-Refaie et al. suggest that regional lymph node dissection may prolong survival time [21]. Ecker et al. support regional lymph node examination for patients with epithelioid and possibly clear cell sarcoma [22]. Brady et al. found that lymph node sampling was associated with improved disease-specific survival in patients with extremity rhabdomyosarcoma (64% vs. 49%, \( P = 0.005 \)) [23]. Riad et al.
showed that resection of involved lymph nodes had an estimated 5-year survival of 57%, whereas nine patients treated without surgery all died within 30 months [24]. In another study, NLND was proved to be an independent risk factor for cancer-specific survival of non-metastatic colorectal sarcomas patients [25]. However, some studies found that lymph node examination/dissection had no impact on prognosis. One study of epithelioid sarcomas found that lymphadenectomy did not improve the overall survival of patients with LNM [26]. Another study found that resection of the metastatic lymph node had better survival at 1.5 years, but did not improve the long-term survival of patients with STS [9]. Some studies argued that the management of positive lymph nodes remains uncertain and that more research is required to assess the impact of lymphadenectomy on the overall survival of STS patients with LNM [3, 10]. The current study suggests that NLND is an appropriate treatment for specific STS patients such as those at high risk for LNM. Nevertheless, we still recommend that patients’ treatment decisions should be based on the clinical reality of the patient, because lymph node dissection may have some acute and chronic complications, such as lymphorrhea, chylous ascites, seroma, delayed wound healing, and chronic lymphedema [27].

This study has some limitations which need to be considered. First, this is a retrospective study and may have inherent limitations, so the results must be validated using prospective studies. Second, the SEER database does not record detailed information about chemotherapy, radiotherapy, comorbidities, complications, and recurrence, which may have a potential impact on the results. Despite these limitations, our findings are of significance.

Conclusion
This study identified the rate of LNM in patients with six STS subtypes of the head, neck, and extremities. In addition, risk factors for LNM and the prognostic factors for STS patients without LNM were further clarified. Most importantly, our study suggests that prophylactic lymph node dissection was necessary and had a clinically beneficial for STS patients at high risk for LNM in the head, neck, and extremities. However, for leiomyosarcoma, NLND did not improve the prognosis and prophylactic lymph node dissection needs to be more carefully evaluated.

Abbreviations
LNM: Lymph node metastasis; STS: Soft tissue sarcomas; NLND: Negative lymph node dissection; SEER: Surveillance, epidemiology, and end results; PSM: Propensity score matching analysis; IQR: Interquartile range; HR: Hazard ratio; CI: Confidence interval; SHR: Sub-distribution hazards ratio; PLN: Positive lymph node group.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13018-022-03050-3.

Additional file 1: Table S1. Univariate logistics and Multivariate Cox analysis of cancer-specific survival for 2756 patients without LNM.

Acknowledgements
We wish to thank the Surveillance, Epidemiology, and EndResults (SEER) Program.

Author contributions
(I) Conception and design were done by HK; (II) Collection and assembly of data were done by QKL and XJY; (III) Data analysis and interpretation were carried out by QKL, XJY, SXW, and RL; (IV) Manuscript review and revision were done by QKL, XJY, YGW, and HRX; (V) Manuscript writing was done by all authors; (VI) Final approval of manuscript was done by all authors. All authors read and approved the final manuscript.

Funding
This study was supported by the National Natural Science Foundation of China (Grant No. 81472106).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The raw data used in this study is derived from the SEER database (https://seer.cancer.gov/), which is a publicly available database. Individual consent for this retrospective analysis was waived because the patient information is anonymous. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 24 November 2021   Accepted: 2 March 2022
Published online: 18 March 2022

References
1. von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(5):536–63.
2. Gutierrez JC, Perez EA, Franceschi D, et al. Outcomes for soft-tissue sarcoma in 8249 cases from a large state cancer registry. J Surg Res. 2007;141(1):105–14.
3. Jacobs AJ, Morris CD, Levin AS. Synovial sarcoma is not associated with a higher risk of lymph node metastasis compared with other soft tissue sarcomas. Clin Orthop Relat Res. 2018;476(3):589–98.
4. Kim JR, Yoon HM, Koh KN, et al. Rhabdomyosarcoma in children and adolescents: patterns and risk factors of distant metastasis. AJR Am J Roentgenol. 2017;209(2):409–16.
5. Nishida Y, Tsukushi S, Urakawa H, et al. High incidence of regional and in-transit lymph node metastasis in patients with alveolar rhabdomyosarcoma. Int J Clin Oncol. 2014;19(3):536–43.
6. Behranwala KA, A‘Hern R, Omar AM, et al. Prognosis of lymph node metastasis in soft tissue sarcoma. Ann Surg Oncol. 2004;11(7):714–9.
7. Miccio JA, Jairam V, Gao S, et al. Predictors of lymph node involvement by soft tissue sarcoma of the trunk and extremity: an analysis of the national cancer database. Cureus. 2019;11(10):e6038.
8. Keung EZ, Chiang Yi, Voss RK, et al. Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. Eur J Surg Oncol. 2018;44(1):170–7.
9. Sawamura C, Matsumoto S, Shimoji T, et al. Lymphadenectomy and histologic subtype affect overall survival of soft tissue sarcoma patients with nodal metastases. Clin Orthop Relat Res. 2013;471(3):926–31.
10. Johannesmeyer D, Smith V, Cole DJ, et al. The impact of lymph node disease in extremity soft-tissue sarcomas: a population-based analysis. Am J Surg. 2013;206(3):289–95.
11. Gusso CA, Fice MP, O’Donoghue CM, et al. A population-based analysis of lymph node metastasis in extremity soft tissue sarcoma: an update. J Surg Res. 2021;262:121–9.
12. Cettoniand F, Martin D, Cherix S, et al. Occurrence and prognosis of lymph node metastases in patients selected for isolated limb perfusion with soft tissue sarcoma. J Cancer. 2018;9:3311–5.
13. Stomeo D, Tulli A, Ziranu A, et al. Acrimetastasis: a literature review. Eur Rev Med Pharmacol Sci. 2015;19(15):2906–15.
14. Persiano C, Scaramuzzo L, De Santos V, et al. Quality of life following surgical treatment of lower limb metastases in long bone. J Biol Regul Homeost Agents. 2015;29(2):501–7.
15. Sherman KL, Kinnier CV, Farina DA, et al. Examination of national lymph node evaluation practices for adult extremity soft tissue sarcoma. J Surg Oncol. 2014;110(6):682–8.
16. Daigeler A, Kuhnen C, Montz R, et al. Lymph node metastases in soft tissue sarcomas: a single center analysis of 1,597 patients. Langenbecks Arch Surg. 2009;394(2):321–9.
17. Amer KM, Thomson JE, Congiusta D, et al. Epidemiology, incidence, and survival of rhabdomyosarcoma subtypes: seer and ices database analysis. J Orthop Res. 2019;37(10):2226–30.
18. Li RH, Zhou Q, Li AB, et al. A nomogram to predict metastasis of soft tissue sarcoma of the extremities. Medicine (Baltimore). 2020;99(21):e20165.
19. Rosenthal J, Cardona K, Sayyid SK, et al. Nodal metastases of soft tissue sarcomas: risk factors, imaging findings, and implications. Skeletal Radiol. 2020;49(2):221–9.
20. Casanova M, Ferrari A, Collini P, et al. Epithelioid sarcoma in children and adolescents: a report from the Italian Soft Tissue Sarcoma Committee. Cancer. 2006;106(3):708–17.
21. Al‑Refae WB, Andtbacka RH, Ensor J, et al. Lymphadenectomy for isolated lymph node metastasis from extremity soft‑tissue sarcomas. Cancer. 2008;112(8):1821–6.
22. Ecker BL, Peters MG, McMillan MT, et al. Implications of lymph node evaluation in the management of resectable soft tissue sarcoma. Ann Surg Oncol. 2017;24(2):425–33.
23. Brady AC, Picado O, Tashiro J, et al. Lymph node sampling and survival in child and adolescent extremity soft-tissue sarcoma. J Surg Res. 2019;241:205–14.
24. Ried S, Griffin AM, Liberman B, et al. Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop Relat Res. 2004;426:129–34.
25. Wei Z, Mao R, Zhang Y, et al. The prognostic factors of primary colorectal sarcoma and the clinical outcomes of negative lymph node dissection. Ann Transl Med. 2021;9(3):250.
26. Ohtani H, Imura Y, Tanaka T, et al. Clinical outcomes of patients with epithelioid sarcoma: impact and management of nodal metastasis. Int J Clin Oncol. 2018;23(1):181–8.
27. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSST-I, an international multicenter trial. Ann Surg. 2005;242(3):302–13.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.